Fast and Furious: Fast Neutron Therapy in Cancer Treatment

Konstantin Gordon, PhD¹,²; Igor Gulidov, PhD ²; Timur Fatkhudinov¹, PhD; Sergey Koryakin, PhD²; Andrey Kaprin, PhD¹,²

¹Federal State Autonomous Educational Institution of Higher Education "People's Friendship University of Russia," Medical Institution, Moscow, Russia
²A. Tsyb Medical Radiological Research Center—branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia

Abstract

Fast neutron therapy has been used for decades. In conjunction with recent advances in photonic techniques, fast neutrons are no longer of much oncologic interest, which is not unequivocally positive, given their undoubted therapeutic value. This mini-review recalls the history of medical research on fast neutrons, considers their physical and radiobiological properties alongside their benefits for cancer treatment, and discusses their place in modern radiation oncology.

Keywords: fast neutrons; cancer treatment; radiation therapy

Introduction

Over the past 2 decades marked by the emergence of intensity-modulated radiation therapy (RT), volumetric-modulated arc therapy, and image guidance, photon therapy more or less has reached its limits. Its further development is restricted by the physical nature of photons. In this context, hadron-based therapies come to the fore as a novel promising option, with proton therapy and carbon-ion therapy centers being the main focus. By 2023, the number of particle facilities in Europe will be increased to 45 [1]. At the same time, the huge potential of particle therapy remains largely underestimated. For instance, classical fast neutron therapy (FNT), a plausible treatment option for cancers at high risk of local recurrence and radioresistant tumors, has been left behind [2, 3].

Neutrons, one of the first known hadrons, have been applied in medicine since their discovery by Chadwick in 1932 [4, 5]. Despite some remarkable clinical outcomes achieved at the dawn of FNT in the 1930s, the growing evidence of severe complications affecting normal tissues put the clinical use of neutrons on a long pause. The approach was reborn in the 1970s after extensive radiobiological research on the dependence of biological endpoints on the linear energy transfer (LET) of the radiation modality. However, after the great splash of interest in the 1970s and 1980s, by the beginning of the 21st-century neutron facilities have all but disappeared and only a few such centers are still functioning.

The unique radiobiological properties of neutrons allow overcoming the multifaceted mechanisms of resistance executed by tumor cells [6–12]. Regardless of the wide availability of conventional photon radiation units and the growing number of proton and C-ion centers, FNT remains a relevant option for certain tumors [13].

The current number of patients having received FNT is just over 35 000, and the sources are restricted to a few databases. The aim of this review was to recall the history and radiobiology of FNT to discuss the experience of its clinical use in cancer patients,
The current state of the field, and its prospects. Numerous important studies illustrating the global FNT experience are listed in Tables 1 and 2.

Fast Neutron Beams, Their Properties, and Radiobiology

Effects of radiation on living tissues depend on multiple factors, including dose levels and microscopic dose distributions, as well as fraction delivery and tissue doubling times. The frequency of lethal events in cells under direct irradiation correlates with LET value. Sparingly and densely ionizing radiation types can be referred to as low-LET and high-LET, respectively. The higher LET, the more severe the DNA damage is and the more complicated the pathways are for its repair. Compared with the conventional low-LET beams, high-LET beams kill cells with higher efficiency [54] explained by indirect oxygen effects and direct damage to DNA [55, 56]. Owing to their direct effect on DNA, high-LET particles act on tumor cells independently of oxygenation, and their relative biological effectiveness (RBE) has little to do with the oxygen enhancement ratio, typically low in the hypoxic tumor microenvironments.

Moreover, high-LET particles have low selectivity regarding cell cycle, affecting cells at different stages of cell cycle progression [57]. This is a consequence of the multiplicity of DNA lesions (clustered DNA damage) produced by single particles. Clinical applications conventionally involve neutrons with RBE = 3 [13], although the value may show complicated behaviors depending on particle energy and fractionation [58–60].

Optimal doses and biological effects of fast neutrons also depend on tissue type; for instance, the dose absorbed in fat is 20% higher than in muscles. Interacting with biomolecules in living tissues, fast neutrons produce protons and the high-LET recoil nuclei of C, N, and O, which poses significant risks of normal tissue side effects [61]. Concurrently, fast neutrons are of historically proven effectiveness toward certain malignancies containing hypoxic cells incredibly resistant to conventional irradiation; the total treatment length can be reduced given the low number of neutron fractions required [62].

Various nuclear reactions (d+T, d+Be, p+Be, and d+T) can be used to obtain fast neutrons in different energy ranges. Production of neutrons by these reactions is accomplished with cyclotrons, linear accelerators, nuclear reactors, or neutron generators. A p+Be reaction is a preferable option for modern, high-energy facilities [63–65].

### Table 1. Studies evaluating fast neutron therapy for brain, head, and neck tumor locations.

| Reference   | Publication date | N of neutron pts | Type of FNT | Compared with photons | Pathology            | Outcomes                  | Toxicity                     |
|-------------|------------------|------------------|-------------|-----------------------|----------------------|---------------------------|------------------------------|
| Caterall [14] | 1977             | 97               | Pure        | Yes                   | H&N c-r              | 1-y OS 53%; 2-y OS 28%    | 4 pts with G4                |
| Maor [15]   | 1983             | 54               | Mixed       | Yes                   | H&N c-r              | LC 44%; OS 20%            | 4 pts with G3–4              |
| Errington [16] | 1986         | 43               | Pure        | No                    | Sinonasal c-r        | 5-y LC 50%; 5-y OS 30%;   | 30% complication rate at 27 mo |
| Mandrynsky [17] | 1991             | 27               | Mixed       | Yes                   | Laryngeal c-r        | 2-y OS 81%                | 3 pts with perichondritis    |
| Liao [18]   | 2014             | 14               | Pure        | No                    | H&N mucosal melanoma | 5-y LC 66%; 5-y OS 21%;   | 4 pts with G3 mucositis, 2 events of osteoradionecrosis |
| Bucholz [19] | 1992             | 53               | Pure        | No                    | Salivary gland ACC   | 5-y LC 77%; 5-y OS 33%;   | 19% of G3, 2 events of death |
| Laramore [20] | 1993             | 13               | Pure        | Yes                   | Salivary gland ACC   | 10-y LC 56%, 10-y OS 15%  | 2 pts with G4                |
| Pötter [21] | 1999             | 72               | Pure        | No                    | Salivary gland ACC   | 3-y LC 73%; 5-y OS 58%;   | 4%–6% acute G3–4; 1 temporal lobe necrosis |
| Douglas [22] | 2003             | 279              | Pure        | No                    | Salivary gland ACC   | 6-y LC 59%; 6-y DFS 67%;  | 10% of late G3–4             |
| Brackrock [23] | 2005            | 71               | Pure        | No                    | Salivary gland ACC   | 6-y LC 45%; 6-y OS 60%    | 9 late G3–4 events           |
| Timoshchuk [24] | 2019            | 545              | Pure        | No                    | Salivary gland ACC   | 10-y LC 79%; 10-y OS 62%  | 3%–7% risk of osteradionecrosis |
| Laramore [25] | 1989             | 38               | Mixed       | Yes                   | Brain AA             | Median OS 1.7 y            |                             |
| Breteau [26] | 1996             | 294              | Mixed       | No                    | Brain GBM            | Median OS 26.7 mo          | 3 documented radionecrosis   |
| Stelzer [27] | 2008             | 10               | Pure        | No                    | Brain GBM            | 1-y OS 66%                | moderate gliosis and microvascular sclerosis at autopsy |
| Sarycheva [28] | 2021             | 40               | Mixed       | No                    | Rec gliomas          | 3-y OS 66.7%              | ND                           |

**Abbreviations:** pts, patients; FNT, fast neutron therapy; H&N, head and neck; c-r, cancer; OS, overall survival; G, grade; LC, local control; ACC, adenoid cystic carcinomas; LRC, local regional control; DFS, disease-free survival; AA, anaplastic astrocytoma; GBM, glioblastoma; Rec, recurrence.
| Reference | Publication date | N of neutron pts | Type of FNT | Compared with photons | Pathology | Outcomes | Toxicity |
|-----------|-----------------|-----------------|-------------|-----------------------|-----------|----------|----------|
| Russel [29] | 1987 | 45 | Mixed | Yes | Prostate c-r | 8-y OS 63% | 25 events with G3–4 |
| Krieger [30] | 1989 | 55 | Mixed | Yes | Prostate c-r | 5-y LRC 81%; 5-y OS 70% | 9% of G3–4 |
| Laramore [31] | 1993 | 55 | Mixed | Yes | Prostate c-r | 10-y LC 70%; 10-y OS 46% | 8 events of G3, 1 death |
| Forman [32] | 2002 | 700 | Mixed | Yes | Prostate c-r | 5-y DFS 93% | 0%–18% of G3–4, depending on neutron dose |
| Caterall [33] | 1987 | 17 | Pure | No | LA Breast c-r | Median OS 26 mo | 3 pts with skin necrosis, 17 pts with moderate fibrosis |
| Smirnova [34] | 1998 | 85 | Mixed | Yes | LA Breast c-r | 5-y OS 71.8; 10-y OS 22.7% | No difference with gamma rays |
| Murray [35] | 2005 | 12 | Pure | Yes | Breast c-r | Median OS 21.5 m | 6 pts with G3–4 |
| Ragulin [36] | 2015 | 95 | Mixed | Yes | Advanced Breast c-r | 10-y OS 32.8%; 10-y DFS 29.5% | No difference with gamma rays |
| Startseva [37] | 2015 | 108 | Mixed | Yes | Breast c-r | 10-y OS 70.8%; 10-y LC 98% | No G3 |
| Velikaya [38] | 2016 | 91 | Mixed | Yes | LA Breast c-r & rec | Rec—8-y OS 87.6%; LA—7-y OS 85.4% | 1 pt with Gr 3 |
| Cohen [39] | 1984 | 51 | Pure | No | Sarcomas | LC 44%–50% | 9 pts with G3–4, 1 death |
| Budach [40] | 1990 | 40 | Sarcomas; 18 CSA | Mixed | No | Sarcomas, CSA | Sarcomas: LC 69.3%; OS 91%. CSA: LC 55.6%; OS 62.9% | No G3 |
| Steingräber [41] | 1996 | 221 | Pure | No | Sarcomas | LC 66% | 40% of severe fibrosis |
| Schwartz [42] | 2001 | 72 | Mixed/Pure | No | Sarcomas | 4-y OS 66% | 15% of G3–4 |
| Morita [43] | 1985 | 45 | Mixed | Yes | Uterine c-r | 5-y 73% | No difference with gamma rays |
| Pointon [44] | 1985 | 48 | Mixed/Pure | Yes | Bladder c-r | T2 stage: 3-y OS 52%. T3 stage: 3-y OS 43% | 10%–37% of G3–4, 4 deaths |
| Maor [45] | 1988 | 80 | Mixed | Yes | LA cervical c-r | 2-y LC 45%; median OS 1.9 y | 19% of G3–4 |
| Eising [46] | 1990 | 20 | Mixed | No | Rectal c-r | Pain-free 9 mo—46%; 1-y OS 56% | 2 pts with severe fibrosis |
| Engenhart [47] | 1990 | 26 | Mixed | No | Rec rectal c-r | Pain relief in 22 pts | 2 pts with G3–4 |
| Patel [48] | 2015 | 30 | Pure | No | Pleural mesothelioma | Median OS 22.1 mo | ND |
| Choinzonov [49] | 2017 | 45 | Mixed | No | Thyroid c-r (postop and rec) | Postop: 5-y OS 70.2%; 5-y LC 52%; rec: 5-y OS 32.8% | 81% of skin G2–3 |
| Bittner [50] | 2008 | 20 | Pure/mixed with brachytherapy (6 pts) | No | Trachea ACC | 5-y OS 89.4% | 2 events of late G3–4 |
| Eichhorn [51] | 1982 | 600 | Mixed | No | Various | 1. Positive effects of mixed RT | 2. Optimal dosage is 1.2–2.0 Gy |
| | | | | | | 3. FNT is better for inoperable pts | |
| | | | | | | 4. Prophylactic postop RT for radioresistant tumors | |
| | | | | | | 5. High sensitivity of spinal cord | |
| | | | | | | 6. Differences in assuming the effects of normal tissue between RT and FNT | |
| Tsunemoto [52] | 1988 | 1623 | Pure | ND | Various | Salivary gland ACC, prostate c-r, sarcomas, melanomas, | |
| | | | | | | pancoast tumor—are indications for FNT | |
| Koh [53] | 1994 | 83 H&N; 99 NSLC; 87 Prostate c-r | Mixed | Yes | H&N, inoperable NSLC, Prostate c-r | H&N: 2-y LC 39%; 2-y OS 36%. NSLC: 2-y LC 85%; 2-y OS 14%. Prostate: 2-y LC 89%; 5-y OS 68% | H&N: 19% of late G3–4. NSLC—ND. Prostate c-r—11% of late G3–4. |

**Abbreviations:** pts, patients; FNT, fast neutron therapy; c-r, cancer; OS, overall survival; G, grade; LCR, local regional control; LC, local control; DFS, disease-free survival; LA, locally advanced; rec, recurrence; CSA, chondrosarcoma; ND, no data; postop, postoperative; ACC, adenoid cystic carcinoma; RT, radiation therapy; H&N, head and neck; NSLC, non–small cell lung cancer.
Clinical Experience

Shortly after the first cyclotron was developed at the University of California, Berkeley, in 1936, Locher et al. [66], Lawrence et al. [6], and Robert [67] suggested using both fast and slow neutrons to treat cancer. The first attempts entailed severe complications and the concept stayed frozen for decades. In 1977, Catterall et al. [14] described positive outcomes of FNT in a randomized clinical trial comparing the use of fast neutrons versus photons or gamma rays in 102 patients with advanced head and neck (H&N) cancers. The study revealed significant advantages of fast neutrons alongside comparable severity of side effects. The authors promoted FNT as a matter of clinical utility and no longer an experimental approach [14]. However, other clinical results were controversial. Along with the strong long-term response to FNT, a significant proportion of the patients developed severe side effects [68] subsequently linked to several problems (ie, RBE miscalculation, fields overlapping, and high total doses) [58, 59].

Initial estimates of the immediate and delayed RBE of fast neutrons were modeled on photon therapy. The aggravated side effects of FNT have been associated with increased reactivity of normal tissues. In particular, the standard RBE of 3 (conventionally applied to estimate the risks of early and late normal tissue reactions) corresponds to higher de facto effectiveness in the late-responding tissues with a low alpha/beta ratio. At lower doses, the atypically high RBE values also contribute to higher toxicity as compared with photon beams or gamma rays of the same megavoltage. It was eventually suggested to combine fast neutrons with photons or gamma rays, thus reducing the toxicity of FNT to acceptable levels [69, 70].

Throughout the 1980s and 1990s, fast neutron facilities grew in number and FNT became an available option for certain tumors, including advanced prostate cancer, breast cancer, and bone and soft tissue sarcomas. In 1985, Peters et al. [69] reviewed FNT studies ongoing in the US. The authors emphasized that the statistically proven benefits of FNT for local tumor control and survival in patients with advanced prostate cancer, H&N tumors, and bladder cancer were dependent on the use of correct treatment schedules and proper neutron sources [69].

Later, Laramore et al. [71] summarized the results of FNT for the allegedly radioresistant bone and soft tissue sarcomas. The study involving 652 patients treated with either neutrons or photons showed a 49% to 55% local control (LC) rate in the FNT group versus 21% to 38% in the photon therapy group, depending on the histological type. No significant differences in adverse events were recorded [71]. For brain gliomas, however, FNT was of no benefit; moreover, the neutron boost had a negative impact on survival, directly related to the deteriorating action of neutrons on nervous tissue [25]. Still, given its specific radiobiological features, FNT remained a promising option for other tumors poorly responding to RT. A final report from the Radiation Therapy Oncology Group–Medical Research Council [20] comparing fast neutrons and photons for the treatment of inoperable salivary gland tumors noted a significant advantage of FNT in terms of LC and a marginal benefit in overall survival (OS), ultimately proposing FNT as the treatment of choice for such tumors.

Koh et al. [53] published the results of ongoing phase III FNT versus photon trials in squamous cell H&N tumors, non–small cell lung cancers, and prostate adenocarcinomas. Contrary to previous studies [15, 67, 68], FNT did not show any considerable advantage for H&N cancers. Despite its shorter time frame (4 weeks cf. 7 weeks for the photons), the use of FNT was associated with a significant increase in toxicity. Simultaneously, for a subgroup of non–small cell lung cancer patients with inoperable tumors, FNT showed better results in terms of both LC and OS (16% versus 3%, \( P < 0.02 \) and 19% versus 6%, \( P = 0.15 \), respectively). In addition, there was a trend of better outcomes for neutron-treated patients with unfavorable prognostic factors (eg, T4/N3 stage, critical condition) [53].

Another seminal paper favoring the use of fast neutrons was published in 1996 [72]. Lindsley et al. [72] reported the benefits of FNT in local regional control of unresectable salivary gland tumors compared with photon RT (respectively, 56% versus 17% efficacy). In 1997, Sur et al. [73] confirmed the primacy of fast neutrons for salivary gland tumors based on a similar comparative evaluation of FNT and photon RT outcomes.

Several clinical trials of FNT indicated an improvement in OS rates for squamous-cell lung carcinoma [72]. For H&N cancers, fast neutrons showed a statistically significant improvement in the overall response rate as compared with photons (70% versus 52%, respectively), with similar survival rates in both groups [72].

In connection with its minor sensitivity to hypoxia, FNT is of profound interest for the treatment of slow-growing tumors, notably prostate adenocarcinomas [29–31]. Koh et al. [53] observed significant advantages of FNT over photons in a cohort of 172 patients with prostate adenocarcinoma (5-year local regional control in 89% versus 68%, respectively), albeit with a higher prevalence of severe complications (11% versus 3% for 5-year observation). In 1998, Lindsley et al. [74] published an encouraging summary of worldwide clinical experience of FNT for prostate cancer, notably the benefits of using mixed neutron-photon beams versus pure fast neutron or photon beams.
The striking clinical effects of pure fast neutrons are intrinsically related to the worst issue of FNT—high levels of severe toxicity. Many protocols implemented a combination of conventional photons and fast neutrons, thus reducing the adverse impact of FNT [13].

As the penetrating capacity of neutron beams was initially low, the output energies have eventually increased to dozens of megavolts. The safety issue was relatively settled; paradoxically, it coincided with the beginning of a decline. The new higher mega-electron volt (MeV) neutron units did not provide clear radiobiological benefits in most clinical trials. For instance, Murray et al [35] showed no differences in the use of 66-MeV neutron versus photon irradiation in breast cancer treatment. Besides, the study was underpowered to demonstrate the benefit of FNT over photons, due to premature closure, without reaching its endpoints.

The progressive development of advanced multileaf collimators opened an era of three-dimensional conformal photon irradiation in the beginning of the 2000s [75]. New technical approaches made the conventional RT both deadlier for tumors and safer for the patients. With its evident toxicity and in the absence of explicit guidelines for its use, FNT hardly stayed in focus for anyone except enthusiastically minded experts. With the radiation protection requirements for patients and staff becoming more restrictive, the number of neutron facilities has progressively gone down [76].

Despite the obvious decline, FNT was not completely ruled out. In 2001, Schwartz et al [42] published the outcomes of FNT in 72 patients with soft tissue and cartilaginous sarcomas treated between 1984 and 1996. These tumors show high rates of local aggressiveness and resistance to chemotherapy and RT. As the treatment resulted in a 4-year OS of 66% for the curatively treated group and a 1-year OS of 62% for the palliation group, FNT was recognized as a reliable option for both curative and palliation protocols.

Micke et al [77] presented the outcomes of FNT for local regional recurrences of pre-irradiated H&N cancers with a promising 1-year OS of 29.3% and tolerable side effects. In theory, fast neutrons are most advantageous when applied to hypoxic cell pools that prevail in H&N tumors. On the other hand, a Cochrane Collaboration overview [78] about the efficacy of RT for oral cavity and oropharyngeal cancer failed to find any significant difference in survival or disease-control outcomes between FNT and conventional photon RT.

In 2002, Forman et al [32] published an extensive data set comprising FNT outcomes for 700 prostate cancer patients treated with neutrons only or mixed neutron-photon beams. The authors identified a 50:50 ratio of neutrons and photons (corresponding to 10 Gy of neutrons and 40 Gy of photons) as the optimal tradeoff between tumor control rates and normal tissue adverse events [32]. These were the last attempts at FNT of prostate cancer, which proved an unfavorable option. The effective alternative treatments for prostate cancer available to date (photon external beam RT, brachytherapy) allow high rates of local control without excessive toxicity; hence the lack of need for FNT in this area.

As for other tumor types, the effectiveness of fast neutrons in the adenoid cystic salivary gland cancers was additionally corroborated by Douglas et al [22] and Brackrock et al [23]. An interesting study estimating the outcomes of FNT and brachytherapy for adenoid cystic carcinoma of the trachea was published in 2008 by Bittner et al [50], presenting excellent results, with a 5-year OS of 89.4% and toxicity within grade 3.

It should be emphasized that a majority of studies on FNT published in the 2000s were based on the data collected in the 1980s and 1990s, and only a few of them, enrolling small cohorts of patients, involved neutron units built after 2000. For instance, Stelzer et al [27] applied FNT to treat 10 patients with glioblastoma; the treatment was carried out under positron-emission tomography guidance. Similar to the previous studies on brain tumors, the low-radiation tolerance of brain tissue critically limited the odds of success, even with the modern conformal techniques and positron-emission tomography [27].

In the 2000s, only a few FNT facilities worldwide were still operating—in the US, Germany, and Russia [13]. The clinical experience of FNT in Russia is remarkable due to the extensive nonmilitary nuclear infrastructure historically related to the advanced physical research in the former Soviet Union. Guliadov et al [79] successfully applied fast reactor neutrons from a nuclear power station to different cancers, mostly H&N and breast cancers. Lukina et al [80] presented the results of mixed neutron-photon treatment for 33 patients with soft tissue sarcomas, achieving 100% response and 42% OS. One of the last fast neutron centers was functioning in Tomsk until the 2010s.

Being a relatively superficial RT target, locally advanced breast cancers also showed a good response to FNT. Moreover, breast cancers remain among the tumors most responsive to FNT. For instance, in a study comprising fast reactor neutron and photon arms, enrolling, respectively, 95 and 106 patients with T4N+ breast cancer, the estimated 10-year survival was, respectively, 32.8% versus 17.1% (P = .02) [36, 81]. Startseva et al [37] achieved a 70.8% 10-year OS in patients with different stages of breast cancer by using 6.3-MeV FNT as a preoperative modality. For recurrent breast tumors, 8-year OS of 87.6% after FNT was reported by Velikaya et al [38].

Gordon et al (2022), Int J Particle Ther
However, local therapy generally aims to achieve acceptable local control with minimal adverse impact on a patient’s life quality. Similar to the case of prostate cancer, a variety of much safer therapy modalities are now available for breast cancer, and FNT is not on this list. Over the last 2 decades, the only clinical value of FNT has been for rare tumors or cases with critically limited actionable opportunities.

For instance, Liao et al [18] reported 5-year local control after FNT in 66% of patients with H&N mucosal melanoma, albeit at survival rates critically undermined because of early distant progression (5-year OS of 21%). Another fatal tumor, pleural mesothelioma, was treated with neutrons by Patel et al [48]; the outcomes were poor as FNT did not bring survival benefits due to the distant expansion of the tumor.

Macomber et al [82] applied FNT for refractory cutaneous Merkel cell carcinoma in a patient with a previous treatment failure; LC was achieved with 18 Gy in 12 fractions and lasted for 2 years. Schaub et al [83] presented 2 promising observations of Merkel cell carcinoma treated with FNT, noting a potential relationship between high-LET neutron beam irradiation and elevated immune response. Choyzonov et al [49] reported 45 patients with resistant forms of thyroid cancer, 32.8% of them responding to FNT (alone or combined with surgery); the only manifestation of local toxicity was skin epidermitis grade 1 to 3.

Overall, salivary gland tumors show the best rates of local response to FNT (10-year LC of 79%) with improved survival rates (10-year OS of 62%) and osteoradionecrosis incidence comparable to photons (2% versus 7%), based on the data for 545 patients [24]. Until 2015, fast neutrons represented an officially recommended RT option for salivary gland cancers, excluded from the guidelines mainly due to its low availability [84].

Prospects

In the new millennium, hadron therapy is a constant focus of attention [85, 86]. The latest technical improvements, cost reduction for the facilities development, and the increasing clinical evidence make the unconventional irradiation quite promising. Alongside protons, heavy carbon ions, and epithermal neutrons, fast neutrons appear highly relevant as well, especially for extremely aggressive and therapy-resistant tumors.

One of the clues to better understanding the clinical controversy associated with FNT lies in the methods of beam generation. The available sources of fast neutrons include cyclotrons, linear proton accelerators, nuclear station reactors, and specific neutron generators. The biological effects of high-LET beams strongly depend on their source, energy, and fractionation. The differences in beam characteristics are partially responsible for the controversy of clinical evidence.

Owing to the inverse dose per fraction effect on RBE, especially in late-responding normal tissues, the trend has eventually shifted toward the use of smaller doses per fraction, with the optimal 10 to 18 Gy corresponding to 1 to 1.8 Gy per fraction [87]. The small-dose schemes of FNT allowed standardization of the treatment and reduced severity of side effects. Mixed irradiation with neutrons and photons or gamma rays, featured in several clinical trials, proved as effective as pure neutrons while being remarkably less toxic as compared with the early low-energy neutron units with inferior beam characteristics and primitive delivery equipment, which negatively affected the clinical outcomes [62, 88].

As fast neutrons have been invariably associated with severe early and late toxicity, it would be reasonable to expect the concomitantly increased risks of radiation-related secondary tumors. Indeed, some of the long-term analyses of secondary malignancies in the aftermath of FNT showed such an increase. For instance, MacDougall et al [89] studied the delayed effects of FNT in 620 patients after RT, with a significant increase of secondary tumors in the FNT population. Similarly, Expósito et al [90] reported an increase in the rates of secondary malignancies based on follow-up clinical data for 1377 patients after FNT.

Despite the allegation of high toxicity of FNT [91, 92] (based on largely outdated sets of clinical evidence in terms of irradiation regimens and equipment used for neutron beam generation), FNT holds great promise for the treatment of various radioresistant tumors with critically limited therapeutic options [93]. Contemporary studies continue to accumulate essential radiobiological data on high-LET therapy involving proton and C-ion irradiation applicable to FNT of similar parameters (eg, Bragg peak, ionization density) [94, 95].

Fast neutron beam radiobiology has multiple abovementioned uncertainties, which are challenging to address. The last decades brought such innovations as advanced multileaf collimators, new means for the neutron beam intensity modulation, and new toxicity correction methods [75, 96–98]. The recent introduction of the Monte-Carlo–based neutron treatment planning system will potentially facilitate the FNT reinvention [93, 99]. Most of the previous FNT results were achieved without even seeing the isodose levels. Recent advances in the intensity modulation allow a 20% to 80% reduction of the fast-neutron beams.
dose to susceptible organs at risk in the H&N area [100]. The latest technical solutions can make neutron generators compact and conveniently transformed into portable cost-effective clinical units [101, 102].

Conclusion

Although fast neutrons have a bad name due to their controversial clinical track record, their overall potential in cancer treatment seems to be underestimated. Based on radiobiological data, fast neutrons might kill tumor cells with comparable effectiveness as the C-ions. Fast neutrons, an established modality for the treatment of certain tumors, can be used for rare radioresistant superficially located tumors, without obvious effective treatment or as a boost in combination with less toxic irradiation modalities. With technological upgrades and randomized trials, fast neutrons are guaranteed a limited, but special, place in modern radiation oncology.

ADDITIONAL INFORMATION AND DECLARATIONS

CRediT: All authors have contributed equally to conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, writing – original draft, writing – review, and editing.

Conflicts of Interest: The authors have no relevant conflicts of interest to disclose.

Funding: The corresponding results were obtained with the financial support of the Ministry of Education and Science of Russia: Agreement of October 7, 2021 No. 075-15-2021-1356 (internal number of the Agreement 15. SIN.21.0011); (RF ID 0951.61321X0012). The funding bodies had no role in the design of the study or collection, analysis, or interpretation of data or in writing the manuscript.

Ethical approval: This review did not involve human subjects/participants and was exempt from institutional review board approval.

References

1. Durante M. Proton beam therapy in Europe: more centres need more research. Br J Cancer. 2019;120:777–8.
2. De Ruysscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, Pijls-Johannesma M. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol. 2012;103:5–7.
3. Suit H, DeLaney T, Goldberg S, Paganetti H, Clasie B, Gerweck L, Niemierko A, Hall E, Flanz J, Hallman J, Trofimov A. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol. 2010;95:3–22.
4. Chadwick, J. Possible existence of a neutron. Nature. 1932;129:312.
5. Lawrence JH, Aebersold PC, Lawrence EO. Comparative effects of X-rays and neutrons on normal and tumor tissue. Proc Natl Acad Sci U S A. 1936;22:543–57.
6. Lawrence JH, Lawrence EO. The biological action of neutron rays. Proc Natl Acad Sci U S A. 1936;22(2):124–33.
7. Bird RP, Burki HJ. Survival of synchronized Chinese hamster cells exposed to radiation of different linear-energy transfer. Int J Radiat Biol Relat Stud Phys Chem Med. 1975;27:105–20.
8. Blakely EA, Chang PY, Lommel L. Cell-cycle-dependent recovery from heavy-ion damage in G1-phase cells. Radiat Res Suppl. 1985;8:S145–57.
9. Barendsen GW, Van Bree C, Franken NA. Importance of cell proliferative state and potentially lethal damage repair on radiation effectiveness: implications for combined tumor treatments (review). Int J Oncol. 2001;19:247–56.
10. Ulianenko SE, Sokolov VA, Potetnya VI, Koryakin SN. Pre-clinical studies on radiation therapy at nuclear reactors and neutron generators in Obninsk. Int J Sci Res. 2006;16:97–100.
11. Asaithamby A, Uematsu N, Chatterjee A, Story MD, Burma S, Chen DJ. Repair of HZE-particle-induced DNA double-strand breaks in normal human fibroblasts. Radiat Res. 2008;169:437–46.
12. Antonelli F, Campa A, Esposito G, Giardullo P, Belli M, Dini V, Meschini S, Simone G, Sorrentino E, Gerardi S, Cirrone GA, Tabocchini MA. Induction and repair of DNA DSB as revealed by H2AX phosphorylation foci in human fibroblasts exposed to low- and high-LET radiation: relationship with early and delayed reproductive cell death. Radiat Res. 2015;183:417–31.
Fast neutrons in cancer therapy

13. Goodhead DT. Neutrons are forever! Historical perspectives. Int J Radiat Biol. 2019;95:957–84.
14. Catterall M. First randomized clinical trial of fast neutrons compared with photons in advanced carcinoma of the head and neck. Clin Otolaryngol Allied Sci. 1977;2:359–72.
15. Maor MH, Hussey DH, Barkley HT Jr, Peters LJ. Neutron therapy for head and neck cancer: II. Further follow-up on the M. D. Anderson TAMVEC randomized clinical trial. Int J Radiat Oncol Biol Phys. 1983;9:1261–5.
16. Errington RD. Advanced carcinoma of the paranasal sinuses treated with 7.5 MeV fast neutrons. Bull Cancer. 1986;73:569–76.
17. Mardynsky YS, Sysoyev AS, Andreyev VG, Gulidov IA. Preliminary results of clinical application of reactor fast neutrons in radiation and combined therapy of patients with laryngeal carcinoma. Strahlenther Onkol. 1991;167:169–71.
18. Liao JJ, Parvathaneni U, Laramore GE, Thompson JA, Bhatia S, Futran ND, Bhrary AD, Hawes SE, Ladra M. Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. Head Neck. 2014;36:1162–7.
19. Buchholz TA, Laramore GE, Griffin BR, Koh WJ, Griffin TW. The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer. 1992;69:2779–88.
20. Laramore GE, Krall JM, Griffin TW, Duncan W, Richter MP, Saroja KR, Maor MH, Davis LW. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993;27:235–40.
21. Pött R, Prott FJ, Micke O, Haverkamp U, Wagner W, Willich N. Results of fast neutron therapy of adenoid cystic carcinoma of the salivary glands. Strahlenther Onkol. 1999;175 Suppl 2:65–8.
22. Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg. 2003;129:944–8.
23. Brackrock S, Krüll A, Röser K, Schwarz R, Riethdorf L, Alberti W. Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. Anticancer Res. 2005;25:1321–6.
24. Timoshchuk MA, Dekker P, Hippe DS, Parvathaneni U, Liao JJ, Laramore GE, Dillon JK. The efficacy of neutron radiation therapy in treating salivary gland malignancies. Oral Oncol. 2019;88:51–7.
25. Laramore GE, Martz KL, Nelson JS, Griffin TW, Chang CH, Horton J. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: does a more aggressive form of treatment adversely impact survival? Int J Radiat Oncol Biol Phys. 1989;17:1351–6.
26. Breteau N, Schlienger M, Favre A, Lescrainier J, Touboul E, Stecken J, Heitzmann A Fast neutrons in the treatment of grade IV astrocytomas. Bull Cancer Radiother. 1996;83 Suppl:135s–41s.
27. Stelzer KJ, Douglas JG, Mankoff DA, Silbergeld DL, Krohn KA, Laramore GE, Spence AM. Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme. Neuro Oncol. 2008;10:88–92.
28. Sarycheva MM, Vazhenin AV, Mozeroava EY, Lozhkov AA, Karabut RYu, Maksimovskaya AYu, Timokhina DM, Sabelnikova ZE. Neutron radiation therapy in the treatment of recurrent high-grade glioma. Sib J Oncol. 2021;20:77–84.
29. Russell KJ, Laramore GE, Krall JM, Thomas FJ, Maor MH, Hendrickson FR, Krieger JN, Griffin TW. Eight years experience with neutron radiotherapy in the treatment of stages C and D prostate cancer: updated results of the RTOG 7704 randomized clinical trial. Prostate. 1987;11:183–93.
30. Krieger JN, Krall JM, Laramore GE, Russell KJ, Thomas FS, Maor MH, Hendrickson FR, Griffin TW. Fast neutron radiotherapy for locally advanced prostate cancer. Update of a past trial and future research directions. Urology. 1989;34(1):9.
31. Laramore GE, Krall JM, Thomas FJ, Russell KJ, Maor MH, Hendrickson FR, Martz KL, Griffin TW, Davis LW. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. Am J Clin Oncol. 1993;16:164–7.
32. Forman JD, Yudelev M, Bolton S, Tekyi-Mensah S, Maughan R. Fast neutron irradiation for prostate cancer. Cancer Metastasis Rev. 2002;21:131–5.
33. Catterall M, Errington RD, Bewley DK. Fast neutrons in the treatment of locally advanced breast cancer. Eur J Surg Oncol. 1987;13:315–9.
34. Smirnova I, Gulidov I, Aminov G. Long-term (5-10 year) results of combined treatment of breast cancer patients using gamma-neutron therapy. Eur J Cancer. 1998;34(1005):S61.
Fast neutrons in cancer therapy

35. Murray EM, Werner ID, Schmitt G, Stannard C, Gudgeon A, Wilson J, Fredericks S, McEvoy E, Nel E, Hunter A, Slabbert JP, Langman G. Neutron versus photon radiotherapy for local control in inoperable breast cancer. *Strahlenther Onkol*. 2005;181:77–81.

36. Ragulin Y, Mardynsky Y, Gulidov I, Aminov G, Medvedev V, Sysoev A, Kotuchov I. 10-year results of complex treatment with reactor neutrons in locally advanced breast cancer (BC). *Ann Oncol*. 2015;26(suppl 3):article 11P.

37. Startseva Z, Musabaeva L, Lisin V. Multimodality treatment of locally-advanced breast cancer using 6.3 MeV fast neutrons and quality of life in patients in long-term follow-up. *Adv Mater Res*. 2015;1084:406–8.

38. Velikaya VV, Musabaeva LI, Lisin VA, Startseva Z A. 6.3MeV fast neutrons in the treatment of patients with locally advanced and locally recurrent breast cancer. *AIP Conf Proc*. 2016;1760:020069.

39. Cohen L, Hendrickson F, Mansell J, Kurup PD, Awschalom M, Rosenberg I, Ten Haken RK. Response of sarcomas of bone and of soft tissue to neutron beam therapy. *Int J Radiat Oncol Biol Phys*. 1984;10:821–4.

40. Budach V, Dinges S, Bamberg M, Baumhoer W, Donhuijsen K, Sack H. Neutron boost irradiation of soft tissue and chondrosarcomas at the West German Tumour Centre in Essen. *Strahlenther Onkol*. 1990;166(1):63–8.

41. Steingraber M, Lessel A, Jahn U. Fast neutron therapy in treatment of soft tissue sarcoma–the Berlin-Buch study. *Bull Cancer Radiother*. 1996;83 Suppl:122s–4s.

42. Schwartz DL, Einck J, Bellon J, Laramore GE. Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. *Int J Radiat Oncol Biol Phys*. 2001;50:449–56.

43. Morita S, Arai T, Nakano T, Ishikawa T, Tsunemoto H, Fukuhisa K, Kasamatsu T. Clinical experience of fast neutron therapy for carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys*. 1985;11:1439–45.

44. Pointon RS, Read G, Greene D. A randomised comparison of photons and 15 MeV neutrons for the treatment of carcinoma of the bladder. *Br J Radiol*. 1985;58:219–24.

45. Maor MH, Gillespie BW, Peters LJ, Wambersie A, Griffin TW, Thomas FJ, Cohen L, Conner N, Gardner P. Neutron therapy in cervical cancer: results of a phase III RTOG Study. *Int J Radiat Oncol Biol Phys*. 1988;14(5):885–91.

46. Eising E, Pötter R, Haverkamp U, Schnepper E. Neutron therapy (dT, 14 MeV) for recurrence of rectal cancer: interim analysis from Münster. *Strahlenther Onkol*. 1990;166:90–4.

47. Engenhart R, Kimmig B, Höver KH, Strauss LG, Lorenz WJ, Wannenmacher M. Photon-neutron therapy for recurrent colorectal cancer–follow up and preliminary results. *Strahlenther Onkol*. 1990;166:95–8.

48. Patel SA, Kusanov AS, Truong A, Stelzer KJ, Laramore GE. Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma. *Am J Clin Oncol*. 2015;38:47–50.

49. Choyzonov E, Gribova O, Startseva Zh, Lisin V, Novikiv V, Musabaeva L. Neutron therapy of resistant thyroid gland cancer. *AIP Conf Proc*. 2017;1882:020015.

50. Bittner N, Koh WJ, Laramore GE, Patel S, Mulligan MS, Douglas JG. Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. *Int J Radiat Oncol Biol Phys*. 2008;72(2):410–4.

51. Eichhorn HJ. Results of a pilot study on neutron therapy with 600 patients. *Int J Radiat Oncol Biol Phys*. 1982;8:1561–5.

52. Tsunemoto H. [Fast neutron therapy in the National Institute of Radiological Sciences; 10 years’ experience and future study]. *Gan No Rinsho*. 1988;34:1833–8.

53. Koh WJ, Griffin TW, Laramore GE, Stelzer KJ, Russell KJ. Fast neutron radiation therapy. Results of phase III randomized trials in head and neck, lung, and prostate cancers. *Acta Oncol*. 1994;33:293–8.

54. Wambersie A, Hendry J, Gueulette J, Gahbauer R, Pötter R, Grégoire V. Radiobiological rationale and patient selection for high-LET radiation in cancer therapy. *Radiother Oncol*. 2004;73 Suppl 2:S1–14.

55. Elkind M, Sutton H. X-ray damage and recovery in mammalian cells in culture. *Nature*. 1959;184:1293–5.

56. Gray I, Conger A, Ebert M, Homsey S, Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. *Br J Radiol*. 1953;26(312):638–48.

57. Terasima T, Tolmach LJ. Changes in X-ray sensitivity of HeLa cells during the division cycle. *Nature*. 1961;190:1210–1.

58. Bradley EW, Alderson PO, Deye JA, Mendenhall KG, Fisher MP, Vieras F, Rogers CC. Effects of fractionated doses of fast neutrons and photons on the normal canine lung: relative biological effectiveness values obtained by radionuclide studies. *Int J Radiat Oncol Biol Phys*. 1979;5:197–207.
Fast neutrons in cancer therapy

59. Awschalom M, Rosenberg I, Mravca A. Kermas for various substances averaged over the energy spectra of fast neutron therapy beams: a study in uncertainties. *Med Phys*. 1983;10:395–409.

60. Baiocco G, Barbieri S, Babini G, Morini J, Aloni D, Friedland W, Kundrát P, Schmitt E, Puchalska M, Sižver L, OttoIenghi A. The origin of neutron biological effectiveness as a function of energy. *Sci Rep*. 2016;6:34033.

61. Gray LH, Mottram JC, Read J, Spear FG. Some experiments upon the biological effects of fast neutrons. *Br J Radiol*. 1995;68:H101–19.

62. Jones DTL, Wambersie A. Radiation therapy with fast neutrons: a review. *Nucl Instrum Meth Phys Res A*. 2007;580:522–5.

63. Cohen L, Lennox A. Midwest institute for neutron therapy at Fermilab. *Int J Radiat Oncol Biol Phys*. 1996;34:269.

64. Mosconi M, Musonza E, Buffler A, Nolte R, Röttger S, Smit FD. Characterisation of the high-energy neutron beam at iThemba LABS. *Radiat Meas*. 2010;45:1342–5.

65. Wagner FM, Kneschaurek P, Kastenmüller A, Loeper-Kabasakal B, Kampfer S, Breitkreutz H, Waschkowski W, Molls M, Petry W. The Munich Fission Neutron Therapy Facility MEDAPP at the research reactor FRM II. *Strahlenther Onkol*. 2008;184:643–6. doi: 10.1007/s00066-008-1878-3

66. Locher GL. Biological effects and therapeutic possibilities of neutrons. *Am J Roentgenol Radium Ther*. 1936;36:1–13.

67. Robert SS, Larkin JC Jr. The treatment of cancer with fast neutrons. *Radiology*. 1942;39:608–20.

68. Stone RS. Neutron therapy and specific ionization. *Am J Roentgenol Radium Ther*. 1948;59:771–85.

69. Peters LJ, Maor MH, Laramore GE, Griffin TW, Hendrickson FR. Review of clinical results of fast neutron therapy in the USA. *Strahlentherapie*. 1985;161:731–8.

70. Eichhorn HJ. Results of a pilot study on neutron therapy with 600 patients. *Int J Radiat Oncol Biol Phys*. 1982;8(9):1561–5.

71. Laramore GE, Griffith JT, Boespflug M, Pelton JG, Griffin T, Griffin BR, Russell KJ, Koh W, Parker RG, Davis LW. Fast neutron radiotherapy for sarcomas of soft tissue, bone, and cartilage. *Am J Clin Oncol*. 1989;12:320–6.

72. Lindsley KL, Cho P, Stelzer KJ, Koh WJ, Austin-Seymour M, Russell KJ, Laramore GE, Griffin TW. Clinical trials of neutron radiotherapy in the United States. *Bull Cancer Radiother*. 1996;83 Suppl:78s–86s.

73. Sur RK, Donde B, Levin V, Pacella J, Kotzen J, Cooper K, Hale M. Adenoid cystic carcinoma of the salivary glands: a review of 10 years. *Laryngoscope*. 1997;107:1276–80.

74. Lindsley KL, Cho P, Stelzer KJ, Koh WJ, Austin-Seymour M, Russell KJ, Laramore GE, Griffin TW. Fast neutrons in prostatic adenocarcinomas: worldwide clinical experience. *Recent Results Cancer Res*. 1998;150:125–36.

75. Farr JB, Maughan RL, Yudelev M, Blosser E, Brandon J, Horste T, Forman JD. Compact multileaf collimator for conformal and intensity modulated fast neutron therapy: electromechanical design and validation. *Med Phys*. 2006;33:3313–20.

76. Wambersie A, DeLuca P M, Caswell R S, Dawson P, Doi K, Feinendegen L, Inokuti M, Kalender W, Menzel H, Michael B, Paretzke H, Seltzer S, Whitmore G F, Taylor L S, Allisy A. ICRU-63: Nuclear Data for Neutron and Proton Radiotherapy and for Radiation Protection Technical Report for the International Commission on Radiation Units and Measurements. Bethesda, MD; 2000. Accessed January 14, 2022. URL: https://www.icru.org/report/nuclear-data-for-neutron-and-proton-radiotherapy-and-for-radiation-protection-report-63/

77. Micke O, Schäfer U, Prott FJ, Schüller P, Scheuber M, Willich N. Fast neutron irradiation in advanced pre-irradiated head and neck tumors. *Tumori*. 2000;86:393–8.

78. Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, Maclusky M, Pavitt S, Chan KK, Brocklehurst P; CSROC Expert Panel. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. *Cochrane Database Syst Rev*. 2010:CD006387

79. Gulidov I, Sysoev A, Mardynsky Yu, Ulianenko S, Buzaev E, Kononov V, Kononov O, Korobeinikov V, Taskaev S. Fast reactor neutrons in the treatment of malignancies and perspectives of NCT and NCT enhanced fast neutron therapy in Obninsk, Russia. In: Arakcheev A, Sudnikov A, eds. *Open Magnetic Systems for Plasma Confinement: Book of Abstracts*. Novosibirsk, Siberia: Budker Institute of Nuclear Physics; 2004:58.

80. Lukina EIu, Vazhenin AV, Kuznetsova AI, Mokichev GV, Munasipov ZZ, Bobkova GG. [Role of fast neutrons in the treatment of soft tissue sarcoma]. *Vopr Onkol*. 2010;56:408–12.

81. Mardynsky Yu, Gulidov I, Aminov G, Ragulin Yu, Kotuchov I, Gordon K. Reactor neutrons in multimodality treatment of locally advanced breast carcinoma. *Adv Mater Res*. 2015;1084:464–6.
82. Macomber MW, Tarabadkar ES, Mayr NA, Laramore GE, Bhatia S, Tseng YD, Liao J, Arbuckle T, Nghiem P, Parvathaneni U. Neutron radiation therapy for treatment of refractory merkel cell carcinoma. *Int J Part Ther*. 2017;3:485–91.

83. Schaub SK, Stewart RD, Sandison GA, Arbuckle T, Liao JJ, Laramore GE, Zeng J, Rengan R, Tseng YD, Mayr NA, Bhatia S, Nghiem PT, Parvathaneni U. Does neutron radiation therapy potentiate an immune response to Merkel cell carcinoma? *Int J Part Ther*. 2018;5:183–95.

84. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LD, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillan N, Hughes M. Head and neck cancers, version 1.2015. *J Natl Compr Canc Netw*. 2015;13:847–56.

85. Goitein M. Trials and tribulations in charged particle radiotherapy. *Radiother Oncol*. 2010;95:23–31.

86. Doyen J, Falk AT, Floquet V, Hérault J, Hannoun-Lévi JM. Proton beams in cancer treatments: clinical outcomes and dosimetric comparisons with photon therapy. *Cancer Treat Rev*. 2016;43:104–12.

87. Catterall M. Neutron therapy. The importance of the technique on clinical results. *Nuc Sci Appl*. 1986;2:235–42.

88. Gulidov IA, Aslanidi IP. On the state and prospects of development of remote neutron therapy. *Vopr Onkol*. 2014;60:408–12.

89. MacDougall RH, Kerr GR, Duncan W. Incidence of sarcoma in patients treated with fast neutrons. *Int J Radiat Oncol Biol Phys*. 2006;66:842–4.

90. Expósito MR, Sánchez-Nieto B, Terrón JA, Domingo C, Gómez F, Sánchez-Doblado F. Neutron contamination in radiotherapy: estimation of second cancers based on measurements in 1377 patients. *Radiother Oncol*. 2013;107:234–41.

91. Abratt RP. Neutron therapy and increased late complication rates. *Radiother Oncol*. 2014;110:375.

92. Spratt DE, Salgado LR, Riaz N, Doran MG, Tam M, Holden S, Katsoulakis E, Rao S, Ho A, Wong R, Lee NY. Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy’s local control superior? *Radiol Oncol*. 2014;48:56–61.

93. Moffitt GB, Stewart RD, Sandison GA, Goorley JT, Argento DC, Jevremovic T, Emery R, Wootton LS, Parvathaneni U, Laramore GE. Dosimetric characteristics of the University of Washington clinical neutron therapy system. *Phys Med Biol*. 2018;63:105008.

94. Kohl T. Die neutronentherapie: ein experimentalsystem der radioonkologie. *Ber Wiss*. 2017;40:368–92.

95. Jones B. Clinical radiobiology of fast neutron therapy: what was learnt? *Front Oncol*. 2020;10:1537.

96. Vazhenin AV, Lukina EIu, Kuznetsova AI, Munasipov ZZ, Mokichev GV. [Prophylaxis of early radiation injuries to intact tissues following exposure to combined photon-neutron radiotherapy for malignant head and neck tumors]. *Vopr Onkol*. 2010;56:404–7.

97. Choynzonov EL, Lisin VA, Gribova OV, Velikaya VV, Startseva ZhA. Methodological approaches to prevention of radiation-induced skin reactions in neutron-photon therapy for malignant neoplasms. *Sib J Oncol*. 2019;18:44–51.

98. Santanam L, He T, Yudelev M, Forman JD, Orton CG, Heuvel FV, Maughan RL, Burmeister J. Intensity modulated neutron radiotherapy for the treatment of adenocarcinoma of the prostate. *Int J Radiat Oncol Biol Phys*. 2007;68:1546–56.

99. Garny S, Rühm W, Zankl M, Wagner FM, Paretzke HG. First steps towards a fast-neutron therapy planning program. *Radiat Oncol*. 2011;6:163.

100. Viscariello N, Greer MD, Parvathaneni U, Liao JJ, Laramore GE, Stewart RD. Comparisons of 3-dimensional conformal and intensity-modulated neutron therapy for head and neck cancers. *Int J Part Ther*. 2021;8:51–61.

101. Jing S, Guo H, Qi Y, Yang G, Huang Y. A portable fast neutron irradiation system for tumor therapy. *Appl Radiat Isot*. 2020;160:109138.

102. Lychagin, AA, Ulyanenko LN, Koryakin SN, Troshina MV, Ulyanenko SE. Determination of absorbed doses in the radiation fields of a neutron generator. *Biomed Eng*. 2019;52:320–5.